Related Experiment Videos
Summary
Chlorambucil, used for polycythemia vera, can cause pulmonary fibrosis. Discontinuing the drug and using steroids improved the patient's lung condition.
Area of Science:
- Pulmonology
- Oncology
- Pharmacology
Background:
- Polycythemia vera is a myeloproliferative neoplasm.
- Chlorambucil is an alkylating agent used in treating polycythemia vera.
Observation:
- A 73-year-old female patient developed pulmonary disease, including cough and dyspnea, during chlorambucil treatment.
- Chest imaging showed interstitial fibrosis and reduced diffusing capacity.
- Pathology revealed alveolar dysplasia, interstitial inflammation, and fibrosis.
Findings:
- Pulmonary symptoms and fibrosis partially resolved after discontinuing chlorambucil and initiating steroid therapy.
- This suggests chlorambucil-induced pulmonary toxicity.
Implications:
- Chlorambucil may induce pulmonary fibrosis, a complication seen with other alkylating agents like busulfan and cyclophosphamide.
- Clinicians should monitor for pulmonary toxicity in patients treated with chlorambucil.